Free Trial

Ionis Pharmaceuticals (IONS) Competitors

Ionis Pharmaceuticals logo
$41.34 -0.44 (-1.05%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$42.15 +0.81 (+1.96%)
As of 07/8/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IONS vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, MDGL, and HALO

Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry.

Ionis Pharmaceuticals vs. Its Competitors

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals and Ionis Pharmaceuticals both had 8 articles in the media. Biogen's average media sentiment score of 0.91 beat Ionis Pharmaceuticals' score of 0.91 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$705M9.33-$453.90M-$2.99-13.83
Biogen$9.68B2.04$1.63B$10.1313.27

Biogen has a net margin of 15.07% compared to Ionis Pharmaceuticals' net margin of -63.65%. Biogen's return on equity of 14.03% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-63.65% -91.85% -15.77%
Biogen 15.07%14.03%8.32%

Ionis Pharmaceuticals currently has a consensus target price of $58.25, suggesting a potential upside of 40.90%. Biogen has a consensus target price of $188.48, suggesting a potential upside of 40.18%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.78
Biogen
0 Sell rating(s)
20 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.38

Ionis Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Summary

Ionis Pharmaceuticals and Biogen tied by winning 8 of the 16 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IONS vs. The Competition

MetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.65B$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.04%
P/E Ratio-13.838.9826.9620.11
Price / Sales9.33729.50430.20119.79
Price / CashN/A159.8036.8257.86
Price / Book11.084.517.985.56
Net Income-$453.90M$31.26M$3.16B$248.40M
7 Day Performance-5.16%3.57%2.39%4.67%
1 Month Performance12.46%1.28%2.18%6.64%
1 Year Performance-12.12%1.08%33.82%21.31%

Ionis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IONS
Ionis Pharmaceuticals
4.5947 of 5 stars
$41.34
-1.1%
$58.25
+40.9%
-12.5%$6.65B$705M-13.831,069
BIIB
Biogen
4.9562 of 5 stars
$125.59
-0.4%
$188.48
+50.1%
-41.0%$18.40B$9.68B12.407,605
INCY
Incyte
4.7635 of 5 stars
$68.10
-0.4%
$74.53
+9.4%
+16.3%$13.18B$4.24B212.822,617Trending News
Insider Trade
UTHR
United Therapeutics
4.9946 of 5 stars
$287.35
+1.1%
$386.15
+34.4%
-7.1%$12.96B$2.88B11.471,305Positive News
Analyst Forecast
NBIX
Neurocrine Biosciences
4.9155 of 5 stars
$125.69
+0.2%
$162.00
+28.9%
-9.5%$12.44B$2.36B42.611,800Positive News
Insider Trade
EXEL
Exelixis
4.7012 of 5 stars
$44.08
+0.9%
$43.56
-1.2%
+97.0%$12.02B$2.17B20.041,147Trending News
Analyst Forecast
Options Volume
BMRN
BioMarin Pharmaceutical
4.9355 of 5 stars
$54.97
-0.4%
$93.45
+70.0%
-29.9%$10.54B$2.85B20.443,040
EXAS
Exact Sciences
4.9347 of 5 stars
$53.14
-1.0%
$70.40
+32.5%
+18.5%$10.02B$2.83B-9.647,000Positive News
Analyst Forecast
RGEN
Repligen
4.7926 of 5 stars
$124.38
+0.7%
$172.83
+39.0%
+7.3%$6.99B$634.44M-276.401,778Analyst Forecast
MDGL
Madrigal Pharmaceuticals
4.0737 of 5 stars
$302.64
+0.6%
$420.63
+39.0%
-1.1%$6.72B$317.38M-16.7790
HALO
Halozyme Therapeutics
4.7712 of 5 stars
$52.02
-0.4%
$61.90
+19.0%
+6.2%$6.41B$1.02B13.84390High Trading Volume

Related Companies and Tools


This page (NASDAQ:IONS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners